Cargando…

Addressing the targeting range of the ABILHAND-56 in relapsing–remitting multiple sclerosis: A mixed methods psychometric study

BACKGROUND: ABILHAND, a manual ability patient-reported outcome instrument originally developed for stroke patients, has been used in multiple sclerosis clinical trials; however, psychometric analyses indicated the measure’s limited measurement range and precision in higher-functioning multiple scle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cleanthous, Sophie, Strzok, Sara, Pompilus, Farrah, Cano, Stefan, Marquis, Patrick, Cohan, Stanley, Goldman, Myla D, Kresa-Reahl, Kiren, Petrillo, Jennifer, Castrillo-Viguera, Carmen, Cadavid, Diego, Chen, Shih-Yin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960866/ https://www.ncbi.nlm.nih.gov/pubmed/29796290 http://dx.doi.org/10.1177/2055217318776990

Ejemplares similares

Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study
por: Strzok, Sara, et al.
Publicado: (2018)

Development and psychometric evaluation of the assessment of self-injection questionnaire: an adaptation of the self-injection assessment questionnaire
por: Pompilus, Farrah, et al.
Publicado: (2020)

Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study
por: Cohan, Stanley, et al.
Publicado: (2018)

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND
por: Repovic, Pavle, et al.
Publicado: (2020)

Results from Patient Interviews on Fatigue in Progressive Multiple Sclerosis and Evaluation of Fatigue Patient-Reported Outcome (PRO) Instruments
por: Watson, Crystal, et al.
Publicado: (2022)

Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021
por: Watson, Crystal, et al.
Publicado: (2023)

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
por: Bell, Jill A., et al.
Publicado: (2019)

Reliability and Validity of the Turkish Version of the ABILHAND-Kids Survey in Children with Cerebral Palsy
por: Şahin, Ebru, et al.
Publicado: (2020)

The Patient Experience of Fatigue in Systemic Lupus Erythematosus: A Conceptual Model
por: Cleanthous, Sophie, et al.
Publicado: (2021)

Correction to: The Patient Experience of Fatigue in Systemic Lupus Erythematosus: A Conceptual Model
por: Cleanthous, Sophie, et al.
Publicado: (2021)

Manual ability in hand surgery patients: Validation of the ABILHAND scale in four diagnostic groups
por: El Khoury, Ghady, et al.
Publicado: (2020)

Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations
por: Simon, Amy, et al.
Publicado: (2018)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

Psychometric Analysis from EMBODY1 and 2 Clinical Trials to Help Select Suitable Fatigue PRO Scales for Future Systemic Lupus Erythematosus Studies
por: Cleanthous, Sophie, et al.
Publicado: (2021)

Understanding the Patient Experience in NUT Carcinoma: Qualitative Interviews with Patients and Caregivers to Develop a Conceptual Framework
por: Pompilus, Farrah, et al.
Publicado: (2021)

The relationship between objective parameters of sleep and measures of fatigue, depression, and cognition in multiple sclerosis
por: Sater, RA, et al.
Publicado: (2015)

Can manual ability be measured with a generic ABILHAND scale? A cross-sectional study conducted on six diagnostic groups
por: Arnould, Carlyne, et al.
Publicado: (2012)

Measuring the impact of multiple sclerosis: Enhancing the measurement performance of the Multiple Sclerosis Impact Scale (MSIS-29) using Rasch Measurement Theory (RMT)
por: Cleanthous, Sophie, et al.
Publicado: (2017)

Pilot study of a ketogenic diet in relapsing-remitting MS
por: Brenton, J. Nicholas, et al.
Publicado: (2019)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30
por: Regnault, Antoine, et al.
Publicado: (2021)

Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study
por: Arnold, Douglas L., et al.
Publicado: (2017)

Psychometric performance of the PROMIS® depression item bank: a comparison of the 28- and 51-item versions using Rasch measurement theory
por: Cleanthous, Sophie, et al.
Publicado: (2019)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial
por: Cree, Bruce A. C., et al.
Publicado: (2021)

Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature
por: Eek, Daniel, et al.
Publicado: (2016)

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
por: Benedict, Ralph HB, et al.
Publicado: (2017)

What They Say in Remitting
Publicado: (1910)

Cortical Shape and Curvedness Analysis of Structural Deficits in Remitting and Non-Remitting Depression
por: Liao, Yuan-Lin, et al.
Publicado: (2013)

Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective
por: Meca-Lallana, José, et al.
Publicado: (2020)

Impulsivity in remitted bipolar disorder
por: Lajmi, I., et al.
Publicado: (2021)

T182. SHARED AND DISTINCT ALTERATIONS IN THE WHITE MATTER TRACTS OF REMITTED AND NON-REMITTED PATIENTS WITH SCHIZOPHRENIA
por: Hwang, Tzung-Jeng, et al.
Publicado: (2018)

Enhanced Functional Connectivity Within Executive Function Network in Remitted or Partially Remitted MDD Patients
por: Wang, Yuchen, et al.
Publicado: (2021)

CCM no. 56
Publicado: (1979)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate
por: Scott, Thomas F., et al.
Publicado: (2021)

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2016)

Patient Uncertainty Questionnaire-Rheumatology (PUQ-R): development and validation of a new patient-reported outcome instrument for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in a mixed methods study
por: Cleanthous, Sophie, et al.
Publicado: (2016)

Smoking Cessation Considerations for People with Multiple Sclerosis
por: Brooker, Christa, et al.
Publicado: (2020)

Relapse recovery: The forgotten variable in multiple sclerosis clinical trials
por: Kantarci, Orhun H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8ip5ihndhkonpq836ctul8rcdm